Hence, the present study was the first to report that the risk of RCR increased to more than 2-fold in rs12916 genotype CC carriers, indicating that HMGCR genetic testing may be utilized to early screen patients with poor efficacy following moderate-intensity statins among those at high risk of CHD. The gene discussed is HMGCR; the disease is coronary artery disorder.